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Abstract
Background: Continued progress towards global reduction in morbidity and mortality due to malaria requires
scale-up of effective case management with artemisinin-combination therapy (ACT). The first case of artemisinin
resistance in Plasmodium falciparum was documented in western Cambodia. Spread of artemisinin resistance
would threaten recent gains in global malaria control. As such, the anti-malarial market and malaria case
management practices in Cambodia have global significance.
Methods: Nationally-representative household and outlet surveys were conducted in 2009 among areas in
Cambodia with malaria risk. An anti-malarial audit was conducted among all public and private outlets with the
potential to sell anti-malarials. Indicators on availability, price and relative volumes sold/distributed were calculated
across types of anti-malarials and outlets. The household survey collected information about management of
recent “malaria fevers.” Case management in the public versus private sector, and anti-malarial treatment based on
malaria diagnostic testing were examined.
Results: Most public outlets (85%) and nearly half of private pharmacies, clinics and drug stores stock ACT. Oral
artemisinin monotherapy was found in pharmacies/clinics (9%), drug stores (14%), mobile providers (4%) and
grocery stores (2%). Among total anti-malarial volumes sold/distributed nationally, 6% are artemisinin
monotherapies and 72% are ACT. Only 45% of people with recent “malaria fever” reportedly receive a diagnostic
test, and the most common treatment acquired is a drug cocktail containing no identifiable anti-malarial. A self-
reported positive diagnostic test, particularly when received in the public sector, improves likelihood of receiving
anti-malarial treatment. Nonetheless, anti-malarial treatment of reportedly positive cases is low among people who
seek treatment exclusively in the public (61%) and private (42%) sectors.
Conclusions: While data on the anti-malarial market shows favourable progress towards replacing artemisinin
monotherapies with ACT, the widespread use of drug cocktails to treat malaria is a barrier to effective case
management. Significant achievements have been made in availability of diagnostic testing and effective treatment
in the public and private sectors. However, interventions to improve case management are urgently required,
particularly in the private sector. Evidence-based interventions that target provider and consumer behaviour are
needed to support uptake of diagnostic testing and treatment with full-course first-line anti-malarials.
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Background
Financing for malaria control has increased substantially
over the last decade, facilitating significant progress
towards international targets for prevention and treat-
ment. Increased coverage of at-risk populations with vec-
tor control as well as effective case management with
artemisinin combination therapy (ACT) is contributing
to substantial reductions in malaria cases and deaths [1].
The spread of artemisinin resistance in Plasmodium
falciparum malaria parasites would threaten recent
malaria control progress across endemic countries. Alter-
native anti-malarial medicines with equivalent levels of
efficacy are not expected to become available for at least
seven to eight years. P. falciparum resistance to artemisi-
nin derivatives has already begun to emerge; the first case
was confirmed in Cambodia, near the Thai border (Pailin
province) in 2009 [2,3].
Factors believed to be contributing to emerging drug
resistance in Cambodia include the unregulated sale of
artemisinin monotherapies for over 40 years; limited
access to ACT; co-blistered ACT which is not co-
formulated (facilitating continued use of artemisinin
monotherapy); and ubiquitous counterfeit and substan-
dard drugs [2]. Cambodia’s resistance containment
programme consists of a number of interventions to
facilitate early diagnosis and appropriate treatment of
malaria. These include a ban on the sale of artemisinin
monotherapies introduced in 2009; ongoing efforts
to strengthen capacity for drug quality monitoring;
a new bureau for policing private drug sellers; and active
efforts to close unlicensed pharmacies [2,4,5]. To facili-
tate diagnosis and treatment with national first-
line drugs, these services are made available at commu-
nity level through a village malaria worker (VMW)
programme implemented in remote provinces [2,6].
Co-blistered artesunate + mefloquine (ASMQ) is the
first-line treatment for P. falciparum and chloroquine is
currently the first-line treatment for P. vivax infections.
In late 2008, the first-line drug in districts with con-
firmed multidrug resistance was changed to dihydroarte-
misinin + piperaquine (DHA+PPQ); public outlets began
stocking the drug in 2009 [2].
Other national malaria control efforts include provision
of highly subsidized rapid diagnostic testing (RDT) and
ACT treatment in the private sector. The international
NGO, Population Services International (PSI) has led pri-
vate sector malaria treatment in Cambodia since 2003.
Private sector ASMQ is sold under the brand name
Malarine and accounts for 75% of the ASMQ distributed
nationally. Rapid diagnostic test kits (RDT) are sold
under the brand name Malacheck. At the time of data
collection for this study, Malacheck tested for P. falci-
parum infections. In 2010, the diagnostic kit changed to
test for both P. falciparum and Plasmodium vivax
infections. Malarine and Malacheck are sold in over
1,700 outlets, including private hospitals, clinics, pharma-
cies, mobile providers and drug stores [4]. In the public
sector, ASMQ is available under the name A+M.
Malaria control in Cambodia is of high significance
globally because of the risk of P. falciparum resistance to
artemisinin, which could develop and spread to sub-
Saharan Africa, crippling malaria control programmes in
high-burden countries. Despite its importance, national
level data on the anti-malarial market and on household
treatment-seeking behaviour are limited. Prior to this
study, national data collection efforts were undertaken by
the national malaria control programme (National Centre
of Entomology, Parasitological and Malaria control, CNM)
in 2007 [7]. Given a dynamic policy and programming
environment, the need for national-level data that can
continually inform targeted malaria control and drug resis-
tance containment efforts is important.
This study uses data collected in 2009 as part of the
ACTwatch research programme [8]. ACTwatch is
designed to provide a comprehensive picture of the anti-
malarial market to inform national and international
drug policy evolution [9]. Cambodia is one of seven ACT-
watch study countries. Nationally-representative outlet
and household surveys were conducted to examine the
supply and demand side of the anti-malarial market. Data
from this study complement existing data on malaria
treatment in Cambodia by providing a comprehensive
picture of the anti-malarial market, including the avail-
ability, price and volumes of various anti-malarials mov-
ing through both the public and the private sector. This
study also presents national data on household treat-
ment-seeking behaviour for “malaria fever.” Results can
be used as part of monitoring access to and demand for
effective combination treatment, as well as availability
and consumption of artemisinin monotherapies. Infor-
mation on consumer and provider behaviour can inform
communications aimed at changing behaviour in the
context of increased access to diagnostic testing and
ACT.
Methods
This study uses data from two nationally-representative
cross-sectional surveys. A survey of outlets with the
potential to sell or distribute anti-malarials was con-
ducted in June through July, 2009. A household survey
was conducted in October through November, 2009.
Data collection coincided with the rainy season during
which malaria transmission occurs; this season generally
begins in late May and ends in December.
Design and sampling
Both outlet and household survey sampling began with
drawing a sample of 38 administrative clusters (health
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centre catchment areas) selected with probability pro-
portional to size (PPS) from stratified lists of the 255
clusters in malaria endemic areas of Cambodia. Equal
allocation stratification was utilized to allow for separate
estimates across two malaria-endemic strata: areas with
confirmed or suspected multidrug resistance and areas
without confirmed/suspected multidrug resistance. A
census of all outlets in these clusters was completed. To
allow for comparisons between outlet types, public
health facilities were also sampled from a larger admin-
istrative “booster” area (district) in which the selected
cluster was located. A total of 7,518 outlets were visited.
In the public sector, these included public health facil-
ities (government referral hospitals, health centres and
posts, N = 211) and village malaria workers (VMW, N =
203). VMWs are stocked with RDTs and anti-malarials
and provide testing and treatment to the community
free of charge. Government health facility staff support
VMWs with initial training, monthly supervision and
stock. Private sector outlets include nationally registered
pharmacies/clinics (pharmacies, clinical pharmacies,
cabinets, and private clinics, N = 152); informal drug
stores (N = 164); grocery stores (shops located in urban
areas, N = 1,170); village shops (shops located in rural
areas, N = 5,144); and mobile providers (N = 383).
Mobile providers are found predominately in rural areas
and serve the communities in which they reside. They
typically possess medical training and are often currently
or previously employed by a public or private sector
facility. Mobile providers interviewed in the outlet sur-
vey provided answers with respect to their drug stock
and practices operating outside the realm of any other
outlet that they are affiliated with. However, some
mobile providers reportedly offer diagnostic testing
using microscopy as part of their practice, in which case
they take blood slides from patients in their mobile pro-
vider practice and use a facility laboratory for diagnosis.
Within the 38 clusters selected with PPS as first stage, a
second stage of selection was used to select six census
enumeration areas per cluster with PPS. Within each cen-
sus enumeration area, 100 households were randomly
selected for screening. The number of households in each
census enumeration area was divided by 100 to derive a
skip interval for random systematic sampling of house-
holds. A total of N = 22,317 households were asked a ser-
ies of screening questions concerning fevers occurring
among household members in the previous two weeks.
While N = 14,306 recent fevers (krun kdao) were identi-
fied, interviews were conducted only among the N = 1,617
people with recent self-reported “malaria fever” (krun
chanh/krun gnak). Most “malaria fevers” included in this
study had occurred among men (62%) and people age 15
and above (71%).
Materials
The core component of the outlet survey instrument is
an exhaustive audit of all anti-malarials in stock at the
time of the survey. For each anti-malarial in stock, identi-
fying information including brand, generic and manufac-
turer names and drug formulation and strength was
collected. Provider reports on unit cost and amount sold
or distributed within the last week was also recorded.
The survey additionally measured availability and price of
microscopic and rapid diagnostic blood testing. Basic
outlet and provider characteristics were collected and
provider knowledge surrounding first-line treatment was
assessed.
The household survey instrument collected detailed
information on treatment-seeking behaviour, including
type, timing, source, and price paid for diagnostic testing
and drugs acquired for fever. Respondent recall and recog-
nition of the type of treatment acquired was aided by the
use of a comprehensive anti-malarial field guide with
photographs and brand names of common anti-malarials
available in public and private sector outlets. This field
manual included pictures of anti-malarial tablets that are
not part of pre-packaged therapies. Where respondents
reported use of a combination of drugs - or a multi-drug
cocktail, the anti-malarial field guide was used to help the
respondent identify anti-malarials contained within the
cocktail, where applicable. Non-anti-malarial cocktail con-
tents (e.g. vitamins, antipyretics) were identified by respon-
dent recall, unaided by a pictorial guide.
The household survey was administered to people age
15 and above with “malaria fever,” and to children’s pri-
mary caregiver where the person with fever was below age
15. In addition to fever management questions, respon-
dents were asked a series of questions assessing their atti-
tudes and knowledge regarding malaria diagnosis and
treatment. A household questionnaire module, modelled
after the Demographic and Health Survey (DHS) [10], col-
lected information on household characteristics and
household assets to be used in assessment of relative
socioeconomic status.
Training and fieldwork
Data collection teams received a six-day training focused
on administration of the questionnaire and sampling pro-
cedures. The outlet survey was conducted in June and
July, 2009. Household survey data were collected from
people with “malaria fever” during the two weeks preced-
ing the survey (or their primary caregiver if under the age
of 15) during the months of September, October and
November, 2009, falling within the peak malaria trans-
mission season. All questionnaires were reviewed by the
team supervisor and spot checks were conducted for at
least 20% of all outlets and households. Microsoft Access
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(©Microsoft Corporation, Seattle, WA, USA) was used for
double data entry and validation. All research activities
operate under ethical approval granted by the Cambo-
dian national ethics review board.
Measures
Anti-malarials identified during the outlet drug audit
were classified according to information on drug formu-
lation, contents and strengths with supporting informa-
tion including brand or generic name and manufacturer.
All outlets visited were classified as having at least one
anti-malarial in stock at the time of the survey or not.
Cotrimoxazole and medicines intended solely for malaria
chemoprophylaxis were not categorized as anti-malarials.
Among outlets stocking anti-malarials, variables were
created to indicate stocks by type, including the broad
category of ACT, as well as specific categories including
all ASMQ, private sector ASMQ sold as Malarine, public
sector ASMQ distributed as A+M, oral artemisinin
monotherapy, and non-artemisinin monotherapy. Avail-
ability of diagnostic testing services was assessed among
outlets stocking anti-malarial(s) on the day of the inter-
view, or that reportedly stocked anti-malarial(s) within
the past three months. Outlets were categorized accord-
ing to availability of rapid diagnostic tests (in stock on
the day of the interview) and microscopic blood testing
(availability of services). Outlet possession of laboratory
equipment in working order was not assessed. Provider
reports on the availability of microscopic blood testing
services - which could entail taking patient blood slides
to another site for testing (particularly relevant in the
case of mobile providers) - were used to classify availabil-
ity of microscopic blood testing.
To calculate volumes of anti-malarials reportedly sold or
distributed in the week preceding the survey as well as
drug prices, drug courses were standardized using adult
equivalent treatment doses (AETD). One AETD was
defined as the amount of the drug needed for a full course
treatment based on guidelines from the WHO where
available. Where unavailable from the WHO, peer-
reviewed literature was consulted, and if necessary, manu-
facturer guidelines were utilized. Provider reports on drug
prices per unit (e.g. tablet) and amount of the drug sold or
distributed during the week preceding the survey were
used to calculate volumes and price according to type of
anti-malarial: Malarine, A+M, other ACT, oral artemisinin
monotherapy, non-oral artemisinin monotherapy and
non-artemisinin monotherapy. The volume of each drug is
therefore the number of AETDs that were reportedly sold/
distributed during the week preceding the survey. The
price of each drug was calculated for one AETD. Audited
anti-malarials with missing data required to calculate
AETD - specifically drug strength - were excluded from
volumes and price estimation.
Household survey indicators of treatment-seeking beha-
viour and treatment of fever were constructed from
respondent reports on sources where treatment was
sought; whether or not the person with fever received a
diagnostic test; self-reported diagnostic test result; source
of diagnostic test and treatment(s); type of treatments
acquired (brand names); and timing of treatments. Brand
names were used to categorize drugs according to generic
anti-malarial types (e.g. chloroquine, quinine, ASMQ).
These were then further classified as ACT, artemisinin
monotherapy, or non-artemisinin monotherapy. Indicators
were calculated using the three classes of anti-malarial
above, as well as an overall category for any anti-malarial.
These anti-malarial drug categories do not include anti-
malarials that were taken as part of a drug cocktail.
A separate category was created to indicate cocktail treat-
ments that contained an identifiable anti-malarial. Another
drug category was created for people who received a cock-
tail of drugs that did not contain any identifiable anti-
malarial.
Sources for diagnosis and treatment were categorized as
either public or private sector. Public health facilities, non-
profit health facilities and village malaria workers (VMWs)
were classified as public sector. The private sector encom-
passes outlets with providers who have formal training
(pharmacies, clinical pharmacies, cabinets, private clinics,
mobile providers) as well as providers who do not gener-
ally have formal training (drug stores, grocery stores,
village shops). Sector in which a person with “malaria
fever” sought treatment was defined as public only, private
only, or a mix of public and private outlets.
Respondent knowledge and beliefs about the first-line
treatment, ASMQ, was assessed through two items. One
dichotomous variable indicates whether or not the
respondent names ASMQ (generic or a brand name) as
an anti-malarial drug. A second measure captured
respondent beliefs on the most effective treatment for
adults with malaria through an open-ended question
that was re-coded into categories including ASMQ and
other ACT.
Socioeconomic status was assessed at the household
level relative to other household respondents, using mea-
sures of housing, water, sanitation and household asset
items modelled after the DHS. Wealth index items were
assigned a weight through principal components analysis
and standardized in relation to a standard normal distribu-
tion. Each respondent was categorized according to their
household’s socioeconomic score, and recorded into one
of five wealth quintiles, ranging from lowest/poorest to
highest/least poor [11].
Data analysis
Frequencies were tabulated for availability of anti-malar-
ials and diagnostic testing by outlet type. Volumes of
Littrell et al. Malaria Journal 2011, 10:328
http://www.malariajournal.com/content/10/1/328
Page 4 of 14
anti-malarials sold or distributed during the previous
week was calculated by considering the fraction of overall
volumes accounted for by the number of AETDs sold/
distributed per anti-malarial drug type (public sector
ASMQ - A+M, private sector ASMQ - Malarine, other
forms of ACT (dihydroartemisinin+piperaquine - DHA
+PPQ, or artemisinin+piperaquine - A+PPQ), oral arte-
misinin monotherapy, non-oral artemisinin monother-
apy, non-artemisinin monotherapy). Frequencies of
AETDs reportedly distributed for free in the public sector
were calculated across drug types: the most popular non-
artemisinin monotherapy, chloroquine; oral artemisinin
monotherapy; Malarine; A+M; and other forms of ACT.
Median price and interquartile range of AETDs sold in
the private sector were calculated across these drug
types. Median price was also calculated for RDTs and
microscopic blood testing available in the private sector.
At the household level, frequencies were tabulated for
source of initial treatment, sector in which treatment was
sought (for those who sought treatment outside of the
home), and source of diagnostic testing and treatments.
Frequencies were also tabulated for number of treatments
acquired for one episode of “malaria fever,” and type of
treatments acquired. Logistic regression was used to test
for an association between treatment-seeking sector (pub-
lic only, private only, public and private) and: 1) diagnostic
testing among all people with fever; 2) anti-malarial treat-
ment of self-reported positive cases, self-reported negative
cases, and undiagnosed “malaria fevers” for which treat-
ment was sought in the public and/or private sector.
Logistic regression was also used to test for an association
between household socioeconomic status and diagnostic
testing among all people with “malaria fever.” Odds ratios
and 95% confidence intervals are reported.
Household data were weighted to account for difference
in the probability of being selected in the different strata.
Standard error estimation accounted for clustering at the
health centre catchment area and enumeration area levels.
Given the use of a census approach, sampling weights
were applied to outlet survey data based on the inverse
probability of selection to account for differences in strata
and cluster sizes and the oversampling of booster outlet
types. Outlet distribution was assumed to be proportional
to population size. Stata 11.0 (©Stata Corp, College Station,
TX, USA) was used for all analyses.
Results
Outlet survey
Most public health facilities (PHF, 85%) and village
malaria workers (VMW, 91%) stock anti-malarials.
Among private sector outlets, percentage of outlets
stocking anti-malarials is highest among pharmacies/
clinics (54%) and drug stores (52%), and relatively low
among grocery stores (8%) and village shops (2%). About
one-third (32%) of mobile providers stock anti-malarial
drugs. Most public sector outlets stock ACT (PHF, 84%;
VMW, 86%). While 49% of pharmacies/clinics and 45%
of drug stores had ACT at the time of the interview,
ACT is less commonly available among mobile providers
(20%), grocery stores (4%) and village shops (1%)
(Table 1).
Most public sector outlets stock ASMQ (PHF, 83%;
VMW, 81%). Fewer than half of all pharmacies/clinics
(44%) and drug stores (44%) have ASMQ in stock. Phar-
macies, clinics and drug stores tend to stock the private
sector ASMQ, Malarine, and stocking of the public sector
A+M is uncommon (pharmacies/clinics, 6%; drug stores,
8%; mobile providers, 5%). These results suggest minimal
leakage of public sector ACT to the private sector. The
category “other ACT” largely refers to dihydroartemisin
+piperaquine (DHA+PPQ), although artemisinin+pipera-
quine (A+PPQ) is also available to some extent. Few pub-
lic sector outlets are stocking other forms of ACT (PHF,
3%; VMW, 7%). However stocking rates are relatively
higher in the private sector: 14% of pharmacies/clinics; 6%
of drug stores; and 3% of mobile providers (Table 1). Con-
sistent with national treatment policy stipulating the use
of DHA+PPQ for the first-line ACT in artemisinin resis-
tance Containment Zone 1 (a recent shift from ASMQ at
the time of the survey), all public sector and most private
sector “other ACT” are found in areas of Cambodia with
suspected or confirmed drug resistance (Zones 1 and 2,
data not shown). Oral artemisinin monotherapies are not
found at PHF. In the private sector, 9% of clinics/pharma-
cies, 14% of drug stores, 4% of mobile providers, and 2%
of grocery stores are carrying oral artemisinin monothera-
pies (Table 1).
Non-artemisinin monotherapies found in the public and
private sector are most commonly chloroquine treatments
(the first-line for P. vivax), although quinine (the second-
line drug for P. falciparum) is also common to some
extent. Non-artemisinin monotherapy is available among
41% of PHF and 55% of VMWs. In the private sector,
stocking rates of non-artemisinin monotherapies are low:
15% of pharmacies/clinics; 16% of drug stores; 14% of
mobile providers; and 4% of grocery stores (Table 1).
Most anti-malarial-stocking public sector outlets have
diagnostic testing available (PHF, 83%; VMW, 76%), with
RDTs (75%) more commonly available in the public sector
as compared with microscopic testing (17%). Among anti-
malarial-stocking private sector outlets, diagnostic testing
is more commonly available within pharmacies/clinics
(74%), drug stores (63%) and mobile providers (74%), and
less commonly available among grocery stores (36%) and
village shops (12%). RDTs are more commonly available in
the private sector as compared with microscopy with the
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Table 1 Percentage of outlets with stock of diagnostic testing and anti-malarials on the day of the interview
Public sector Private sector
Public Health
Facility
Village malaria
worker
Public
sector
total
Pharmacy/
Clinic
Drug
Store
Grocery
Store
Village
shop
Mobile
Provider
Private
sector
total
All outlets, % stocking: N = 211 N = 203 N = 414 N = 152 N = 164 N = 1,170 N = 5,144 N = 383 N =
7,013
Any anti-malarial 85.0 91.1 88.4 53.7 51.9 7.8 2.4 32.4 7.2
Any ACT 83.6 86.3 85.1 49.0 45.4 4.0 0.9 19.9 4.5
Any ASMQ1 82.9 80.8 81.7 44.2 43.6 3.8 0.8 18.2 4.2
A+M1 81.3 80.8 81.0 5.6 7.8 0.1 0.1 5.0 0.7
Malarine1 3.5 0.3 1.7 40.6 38.4 3.8 0.7 16.4 3.8
Other ACT2 2.8 6.5 4.8 13.7 5.5 0.3 0.2 2.6 0.8
Oral artemisinin
monotherapy 0.0 3.7 2.1 9.4 13.8 2.0 0.5 4.2 1.5
Non-artemisinin
monotherapy 40.7 55.1 48.8 14.9 16.1 4.1 1.5 14.1 3.3
Outlets stocking any anti-malarial in the past 3 months,
% stocking:
N = 183 N = 192 N = 375 N = 96 N = 103 N = 91 N = 151 N = 202 N = 643
Any diagnostic test 83.3 76.2 79.1 73.6 62.8 35.8 11.8 74.2 51.9
RDT 74.0 76.2 75.3 57.9 38.5 33.6 8.7 41.5 34.2
Microscopy 36.9 2.1 16.7 37.9 32.3 3.6 3.7 45.2 26.1
1 Private sector ASMQ sold under the name Malarine and public sector ASMQ distributed under the name A+M
2 Other ACTs are DHQ+PPQ or A+PPQ
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exception of mobile providers; 42% have RDTs in stock
and 45% report providing microscopic testing services
(Table 1).
Figure 1 shows the relative volumes of anti-malarial
medicines that were sold or distributed by all outlets in
the past week. The public sector accounts for 29% of the
total market share, and this is largely comprised of
ASMQ; public sector ASMQ accounts for 26% of the
total volumes. The private sector accounts for 71% of the
total market share, and this is accounted for primarily by
ASMQ (32% Malarine, 3% A+M) and non-artemisinin
monotherapy (19%). Across sectors, most of the anti-
malarials sold/distributed are ACT (72%), including
Malarine (33%), A+M (28%), and other ACT - primarily
DHA+PPQ (11%). Non-artemisinin monotherapies - pri-
marily chloroquine - account for 19% of the total
volumes, and oral artemisinin monotherapies account for
6% of total volumes (Figure 1).
Anti-malarials and diagnostic testing are reportedly dis-
tributed free of charge in the public sector in Cambodia,
although service fees typically apply. In the private sector,
the median price charged for an adult equivalent treat-
ment dose (AETD) of the most popular non-artemisinin
monotherapy is just $0.27 (IQR = $0.23-$0.46), compared
with $1.18 (IQR = 0.82-1.65) for private sector Malarine
and $2.12 (IQR = $1.69-$2.17) for other types of ACT.
An oral artemisinin monotherapy AETD is reportedly
distributed for a median price of $3.62 (IQR = $3.01-
4.52). RDTs are sold for a median price of $0.35 (IQR =
$0.24-$0.47), and the median price for microscopic test-
ing in the private sector is $0.71 (IQR = $0.59-$1.18)
(Table 2).
When asked to name the recommended first-line
treatment for uncomplicated P. falciparum malaria, 76%
of all providers in the public and private sector stated
the correct response of ASMQ. Knowledge is highest
among providers in PHF and VMWs (96%) and in pri-
vate pharmacies/clinics (88%), and lower among provi-
ders in drug stores (74%), mobile providers (76%),
grocery stores (64%) and village shops (47%) (Table 3).
Household survey
Among people with recent “malaria fever,” nearly half
(45%) first do something at home to treat the fever; 44%
seek treatment in the private sector; 7% seek treatment in
the public sector; and 4% have not yet done anything to
treat the fever at the time of the interview (Figure 2).
Among those people who seek treatment outside of the
home at some point during the fever episode (86%), most
go to just one outlet type (75%, Table 4). Among those
seeking treatment outside of the home, 79% seek treat-
ment exclusively in the private sector; 10% exclusively in
the public sector; and 11% in both the public and private
sectors (Figure 2).
Nearly half (45%) of all people with recent “malaria
fever” reportedly receive a diagnostic test. Most of these
tests are RDTs (60%), while 31% are microscopy and 10%
of respondents are unsure about the test type. A large
percentage of those tested, 87%, report receiving a posi-
tive diagnosis; 11% reportedly receive a negative result
and 1% do not know the test result (Table 5).
Table 2 Median private sector price of anti-malarials and
diagnostic tests
N Median price (IQR)
Chloroquine1 58 $0.27 ($0.23, $0.46)
Oral artemisinin monotherapy 121 $3.62 ($3.01, $4.52)
Malarine (ASMQ) 338 $1.18 ($0.82, $1.65)
Other ACTs2 62 $2.12 ($1.69, $2.17)
RDT 208 $0.35 ($0.24, $0.47)
Microscopy 174 $0.71 ($0.59, $1.18)
1 Chloroquine is the most popular non-artemisinin monotherapy on the
market
2 Other ACTs are DHA+PPQ or A+PPQ
Table 3 Percentage of providers in anti-malarial-stocking
outlets who correctly state the recommended first-line
treatment for uncomplicated malaria
N %
Public health facility &
village malaria worker
372 96.1
Pharmacy/clinic 96 87.8
Drug store 101 73.7
Grocery store 91 64.4
Village shop 152 47.2
Mobile provider 202 76.2
Figure 1 Volumes of anti-malarial medicines sold/distributed in
the past week.
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People with “malaria fever” who seek treatment exclu-
sively in the public sector are significantly more likely to
receive a diagnostic test than those who seek treatment
solely in the private sector (OR = 4.52, 95% CI = 2.27-
9.00). Diagnostic testing is high among those who seek
treatment in the public sector only (77%) or in the public
and private sector (70%) as compared with those who
seek treatment in the private sector only (42%). Com-
pared to people living in the poorest households, those in
the least poor households are significantly more likely to
receive a malaria diagnostic test (OR = 1.64, 95% CI =
1.05-2.55) (Table 6).
Table 7 examines anti-malarial treatment in the public,
private and public/private sectors across diagnostic test
result. Among people who report a positive diagnostic test
result, those who seek treatment exclusively in the public
sector are significantly more likely to receive anti-malarial
treatment as compared with those who seek treatment
solely in the private sector (OR = 2.15, 95% CI = 1.39-
3.33). Nonetheless, only 61% of people reporting a positive
test result and treated in the public sector report receiving
an anti-malarial, as compared with 54% of reportedly posi-
tive cases seen in the public and private sector, and 42% of
cases seen exclusively in the private sector (Table 7).
While none of the reportedly negative cases treated
solely in the public sector report receiving an anti-malarial,
14% of those treated in the private sector and 13% of those
treated in the public and private sectors reportedly receive
anti-malarial treatment. Among those people who did not
receive a diagnostic test but sought treatment outside of
the home, there is no significant difference in anti-malarial
treatment across treatment-seeking sector (private only,
11%; public only, 25%; public and private, 17%) (Table 7).
About half of all people with “malaria fever” report
taking one anti-malarial or cocktail treatment (54%).
Another 21% report taking two anti-malarial and/or
cocktail treatments, and 7% report taking three or more
of these treatments. Eighteen percent had not yet taken
any anti-malarial or cocktail treatment for the fever at
the time of the survey. Most people with “malaria fever”
report receiving a cocktail of drugs; 47% receive a cock-
tail with no identifiable anti-malarial, and another 11%
receive a cocktail with anti-malarial(s) included in the
mix. An anti-malarial treatment, without cocktail treat-
ment, was reportedly received by just 15% of people
with “malaria fever.” Anti-malarial plus cocktail treat-
ment was received by 10% of people with fever (Table
8). Most of the anti-malarials acquired for treatment of
“malaria fever” are ACT (58% ASMQ, 7% other types of
ACT), however 15% are artemisinin monotherapies and
20% non-artemisinin monotherapies - primarily chloro-
quine (Figure 3).
Table 4 Percentage of people with “malaria fever” who seek treatment outside of the home, and number of outlet
types visited
N %
Seek treatment outside of the home 1,617 86.1
Number of outlet types visited for treatment, among those who seek treatment: 1,386
One ............ 74.7
Two ............ 22.8
Three ............ 2.5
A. Initial place for treatment 
(N=1,617 fevers) 
B. Treatment-seeking sector, among those 
seeking treatment outside of the home 
(N=1,386 fevers) 
Figure 2 Initial place treatment was sought and sector sought for treatment outside of the home.
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The private sector is the most common source
reported for diagnostic testing (70% of people tested)
and anti-malarial treatment (69% of anti-malarial treat-
ments acquired). Cocktail treatments are acquired pri-
marily from the private sector (90% of cocktails
containing an anti-malarial, 89% of cocktails with no
identifiable anti-malarial) (Figure 4)
Discussion
Availability, volumes and use of anti-malarials and
diagnostic testing
Outlet and household survey results show that the sale of
artemisinin monotherapies is still a problem in Cambodia,
however use is limited. Oral artemisinin monotherapies
account for 6% of total anti-malarial volumes sold/distrib-
uted according to outlet survey results, and 15% of anti-
malarial treatments reportedly consumed by individuals
with “malaria fever” according to household survey results.
Availability is limited primarily to the private sector and
stocking rates are relatively low; oral artemisinin mono-
therapy is found in about one in ten pharmacies, clinics
and drug stores and among 4% of mobile providers and
2% of grocery stores. Median price of a full course of
treatment for an adult (i.e. seven days) in the private sector
($3.62) is more than 13 times the price for a full course of
chloroquine ($0.27), and three times the price of private
sector ASMQ, Malarine ($1.18). However, it is important
to note that in practice, the limited use of artemisinin
monotherapy is likely in the form of less expensive incom-
plete doses rather than full-course treatments. The cost of
an adult equivalent treatment dose reported in this study
does not reflect what consumers likely pay when they
obtain oral artemisinin monotherapy, and therefore cost
may not be a significant barrier to use. Previous studies in
Cambodia have documented widespread availability and
Table 5 Diagnostic testing among people with “malaria
fever”
N %
Received a diagnostic test 1,551 44.9
Type of test, among those tested 698
RDT ............ 59.5
Microscopy ............ 30.5
Don’t know ............ 10.0
Self-reported test result, among those tested 698
Positive ............ 87.4
Negative ............ 11.4
Don’t know ............ 1.2
Table 6 Malaria diagnostic testing across treatment-
seeking sector and across relative household wealth
N Received a diagnostic test
% OR (95% CI)
Treatment-seeking sector
Private only 1,094 42.2 1.00
Public only 145 76.8 4.52 (2.27-9.00)***
Public & private 147 69.8 3.15 (1.81-5.48)***
Household wealth
Lowest 339 41.9 1.00
Low 309 42.1 1.01 (0.71-1.44)
Middle 271 49.7 1.37 (0.99-1.90)
High 318 40.0 0.85 (0.63-1.16)
Highest 314 54.1 1.64 (1.05-2.55)*
* p < 0.05 **p < 0.01 ***p < 0.001
Table 7 Anti-malarial treatment acquired for “malaria
fever” across treatment-seeking sector according to self-
reported malaria diagnostic test result
N Received any anti-malarial
% OR (95% CI)
Reported positive test
Private only 409 41.8 1.00
Public only 99 60.7 2.15 (1.39-3.33)**
Public & private 80 53.9 1.63 (0.89-2.98)
All positive cases 588 46.6 —
Reported negative test:
Private only 48 13.5 1.00
Public only 11 0.0 —
Public & private 23 12.6 0.92 (0.17-5.20)
All negative cases 82 11.4 —
No diagnostic test:
Private only 630 11.4 1.00
Public only 34 25.3 2.64 (0.66-10.59)
Public & private 44 16.7 1.57 (0.58-4.24)
All cases without testing 708 12.3 —
* p < 0.05 **p < 0.01 ***p < 0.001
Table 8 Treatment acquired among people with “malaria
fever”
%
(N = 1,617
fevers)
Number of treatments acquired (cocktails and
anti-malarials)
Zero 17.7
One 53.8
Two 21.4
Three or more 7.16
Type of treatment received
Anti-malarial(s) only 14.5
Anti-malarial(s) plus cocktail(s) 9.9
Cocktail(s) containing an anti-malarial 10.6
Cocktail(s) with no identifiable anti-malarial only 47.4
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use of artemisinin monotherapies [12,13]. Recent efforts to
control the use of monotherapies have included a ban on
artemisinin monotherapies and active enforcement of this
ban [2]. Results from this survey show that in 2009, pro-
gress was being made towards eliminating their use, but
continued efforts are still needed.
ACT sales and distribution are high in Cambodia, and
the majority of ACT formulations sold/distributed are the
first-line drug, ASMQ. ACT account for 72% of anti-
malarial volumes sold/distributed, and for 65% of anti-
malarial treatments reportedly acquired for “malaria
fever.” The use of non-artemisinin monotherapies, largely
chloroquine, accounts for 19% of volumes and 20% of
treatments reportedly acquired for fever. At the time of
these surveys, chloroquine was the first-line treatment for
P. vivax infections, and therefore availability and use of
this drug cannot necessarily be considered unfavourable.
The relatively high use of ACT appears to be in part
supported by favourable availability. Most public health
facilities (84%) and VMWs (86%) provide ACT, and nearly
half of private pharmacies, clinics and drug stores stock
ACT. The stocking rates of non-artemisinin monothera-
pies (primarily chloroquine) are substantially lower: about
half of public health facilities and only about 15% of phar-
macies, clinics and drug stores stock these drugs. Favour-
able availability of ACT in the private sector is supported
by the national private sector subsidy for the sale of
ASMQ marketed as Malarine [4]. This mature subsidy
programme was in operation at scale for five years prior to
this study, and results point to the success of the pro-
gramme. Results from this study show that one-third of all
anti-malarials reportedly sold/distributed in Cambodia are
Malarine treatments. Favourable availability of ASMQ in
the public sector - including public health facilities and
among community-based village malaria workers - illus-
trates the success of national efforts to ensure availability
of effective treatment in the public health system.
In line with WHO guidelines [14], national policy in
Cambodia specifies that all people with suspected malaria
should first receive a diagnostic test [1]. Findings from
this study show that only 45% of people with “malaria
fever” in Cambodia receive a diagnostic test. The outlet
survey results show that diagnostic testing is often avail-
able within anti-malarial-stocking facilities, and that
RDTs are more commonly available as compared with
microscopic testing. Approximately eight in ten public
outlets, three-quarters of anti-malarial-stocking pharma-
cies and clinics, and well over half of anti-malarial-stock-
ing drug stores (63%) provide diagnostic testing. Higher
levels of availability in public health facilities and with
VMWs could be contributing to higher frequency of
diagnostic testing among people seeking treatment in the
public sector (77% of fevers tested) as compared with
those who are treated exclusively in the private sector
(42%). Another barrier to diagnostic testing is cost:
household survey results find that diagnostic testing is
 A. Source of testing 
 
(N=698 people tested) 
B. Source of anti-malarials 
 
(N=387 anti-malarials) 
C. Source of cocktails 
containing an anti-malarial 
(N=200 people treated) 
D. Source of cocktails with no 
identifiable anti-malarial 
(N=1,188 people treated) 
Figure 4 Source of diagnostic testing, anti-malarial treatments, and cocktail treatments.
Figure 3 Type of anti-malarials reportedly acquired for
“malaria fever” (N = 426 anti-malarials).
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significantly higher among people from the relatively
least poor households as compared to the very poorest.
RDTs are available in the public sector free of charge, but
with a fee for service, and providers in the private sector
report a median RDT price of $0.35. Although RDTs are
already heavily subsidized [4], the added cost of testing
may still be prohibitive for the very poor.
Price of diagnostic testing and treatment in the private
sector is particularly relevant in Cambodia because it is
much more frequently accessed for fever diagnosis and
treatment. Household survey results show that most peo-
ple eventually seek treatment outside of the home for
“malaria fever,” (86%), and that 79% of these treatment-
seekers seek care exclusively in the private sector. An
additional 11% seek care in both the public and private
sectors. About 70% of diagnostic tests and anti-malarial
treatments are acquired in the private sector, which tri-
angulates with outlet survey results showing that 71% of
anti-malarial volumes are sold/distributed through the
private sector. Similar findings have been reported else-
where [7,12], and point to the importance of considering
the private sector in efforts to improve effective fever
management and eliminate the use of artemisinin mono-
therapies. While significant achievements have been rea-
lized in making RDTs and ACT available in private
outlets - particularly pharmacies/clinics and drug stores,
results from this study suggest that private sector
improvements should include further expansion of pri-
vate sector availability as well as appropriate sale/use of
RDTs and full-course anti-malarial treatments. Where
sub-optimal availability of testing and treatment remains
in private sector outlets, it is essential that private provi-
ders refer clients with “malaria fever” to public or private
outlets where testing and appropriate treatment are avail-
able. Interventions to strengthen linkages between private
and public providers are important in Cambodia where
people frequently seek treatment in the private sector.
CNM and its partners are currently pursuing a public-
private mix (PPM) approach that entails training, incen-
tive systems and a certification program for private provi-
ders [15].
Cocktail treatments
ACT availability and price are favourable, particularly
compared to artemisinin monotherapies. Further, the
proportion of anti-malarials that are sold/distributed and
reportedly consumed in Cambodia are overwhelmingly
ACT. However, household study results show that the
state of “malaria fever” management in Cambodia is far
from ideal. Findings from this national study confirm
results from smaller quantitative [12,13,16] and qualita-
tive [17] studies on the widespread use of cocktail treat-
ments in Cambodia’s private sector. Cocktail treatment
for suspected malaria in Cambodia typically consists of a
small plastic bag containing one or more tablets of var-
ious drugs including antipyretics, vitamins, anti-malarials,
antihistamines and antibiotics [12,13]. Cocktail treatment
presents a significant barrier to full-course treatment.
Those seeking treatment may not be provided with the
full course, either due to provider practices or cost of
treatment. Even if they happen to receive a full course of
anti-malarial treatment as part of a cocktail, consumers
may not receive adequate information on the cocktail
contents and instructions for complying with the treat-
ment regimen.
Among all people with “malaria fever,” only 15% report
receiving an anti-malarial treatment only (without
acquiring cocktail treatment). Another 10% receive an
anti-malarial as well as cocktail treatment. Higher levels
of anti-malarial treatment occur when a diagnostic test
result is positive, particularly in the public sector. How-
ever, despite the fact that most public outlets stock anti-
malarials (88%), only 61% of people who reported a posi-
tive test and were treated exclusively in the public sector
reported receiving anti-malarial treatment. Lower levels
of treatment of positive cases in the private sector (42%)
could be due to less favourable availability of anti-malar-
ials in the private sector. Anti-malarial stock-outs may
account for some of the poor case management practices
in both the public and private sectors. However, these
results suggest that further examination of case manage-
ment practices in both the private and public sectors is
needed to understand prescribing and dispensing beha-
viour regardless of stocking rates. Interventions that aim
to improve fever management and prevent further devel-
opment of artemisinin-resistant parasites by improving
price and availability of effective combination treatments
require supporting interventions targeting provider and
consumer behaviour and preferences [18]. Interventions
to improve appropriate treatment rates such as provider
training and supervision are particularly needed in the
private sector as its performance lags behind the public
sector and it is the source of the majority of cocktail
treatments. Approaches currently being explored in
Cambodia to improve private provider knowledge and
practices include medical detailing [19] and strengthened
public-private partnerships [15].
Effective interventions to target the widespread use of
cocktail treatments in the private sector will require
much more information on what transpires between pro-
viders and clients when clients present with “malaria
fever.” While this study and others conducted to-date
document the common practice of cocktail treatment
[12,13,16,17], there is need for studies of provider and
consumer beliefs and behaviour contributing to these
practices. This information can be used to identify key
areas for changing knowledge, attitudes and behaviour
with respect to cocktail treatment. Research could
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include qualitative and quantitative studies focused more
specifically on the use of cocktails for treating illness
more broadly, as opposed to the narrow scope of the stu-
dies presented here - focused solely on the anti-malarial
market and household treatment of “malaria fever.”
Study limitations and need for additional research
There are a number of limitations to this study, which
may be important for interpretation of results regarding
the anti-malarial market as well as diagnosis and treatment
of suspected malaria. First concerning the anti-malarial
market, estimating relative volumes of anti-malarials sold/
distributed in the week prior to the survey relies upon
converting the amount of each drug reportedly sold/dis-
tributed into a comparable unit - the adult equivalent
treatment dose (AETD). However, anti-malarials may be
sold/distributed in sub-standard doses. The use of AETDs,
therefore, systematically underestimates the actual market
share of anti-malarials that are sold/distributed in sub-
standard doses. This is a concern particularly with respect
to oral artemisinin monotherapy, where the AETD is cal-
culated as a seven-day treatment however the amount
sold/distributed may often be sub-standard. Additionally,
the methodology of calculating AETD is limited when
AETD cannot be calculated due to missing information.
Missing data that prohibit volumes calculation include
missing strength information, which can occur when loose
tablets are stored in unlabelled or partially labelled con-
tainers. In other cases, information on the volumes sold/
distributed is missing. In this study 14% of the N = 2,036
audited anti-malarials were excluded from the volumes
calculation due to missing information. Excluded anti-
malarials were primarily chloroquine (38%) and quinine
(27%), meaning that the relative volumes estimates
reported in this study underestimate the contribution of
these non-artemisinin monotherapies. Anti-malarials
excluded from volumes calculations are primarily from the
private sector (80%), particularly from village shops (29%)
and other small-scale providers. The relatively high contri-
bution of the private sector to national sales volumes
reported in this study is therefore a conservative estimate.
Household survey results rely on respondent recall
regarding diagnostic testing, testing results and subse-
quent treatment. A very high proportion of those who
received a diagnostic test reported positive results (88%).
The category of respondents in this study who report-
edly had a positive test result could be over-inflated and
perhaps better represents perceived positive rather than
actual positive test results. Another limitation that could
have contributed to this high positivity rate is the
screening process, which aimed to identify people who
had “malaria fever.” People who tested negative may
have responded “no” to the question on recent “malaria
fever,” because they received a confirmed negative
diagnosis. However, the extent of this exclusion seems
limited given that previous studies [13], including the
CNM 2007 national household survey focused on fever
have also found very high self-reported positivity rates
[7]. Gathering unbiased information on diagnostic test
results through household surveys is generally a chal-
lenge and a barrier to constructing relevant, unbiased
treatment outcome indicators where policy dictates
treatment based on test results.
One of the key aims of the household survey was to
gather information on the consumer side of the anti-
malarial market. As such, the household survey focused
on self-reported “malaria fevers” because, given relatively
low malaria prevalence in Cambodia, studying all fevers
would be unlikely to yield sufficient information on anti-
malarials consumed. Balancing the need to gather infor-
mation about anti-malarials acquired and consumed with
limited time and money for fieldwork required this focus.
To obtain information on just N = 426 anti-malarial treat-
ments acquired by households, over 22,000 households
were screened and N = 1,617 fever episodes were studied.
In comparison, the 2007 CNM survey focused on treat-
ment-seeking behaviour for fever conducted N = 1,316
interviews and obtained information on just N = 93 anti-
malarials [7]. Results from this study are therefore useful
in understanding treatment-seeking behaviour among
people who suspect that they have recently been infected
with malaria, and are not necessarily adequate for under-
standing actions taken when any fever strikes.
Reported use of cocktails was very common in this
study, and most of these cocktails were obtained in the
private sector (90%). Respondent reports of cocktail treat-
ments in the household survey could refer to the small
plastic bags containing multiple types of drug tablets.
However it is possible that respondents also referred to
receipt of multiple drugs - including partial and/or full-
course treatments from one source - as a cocktail. The lat-
ter definition of a cocktail is no doubt represented to
some extent in the data, given that 10% of “cocktails” were
obtained in the public sector, where presumably small
plastic bags containing multiple types of drug tablets are
not distributed. Further research is needed to document
dispensing practices, particularly in the private sector so as
to understand the range of treatments that are defined as
“cocktails” by consumers.
The nature of cocktail treatments - a mixture of various
unmarked tablets and/or blister packages - makes identi-
fication of what exactly was consumed by respondents
very difficult. Every effort was taken to improve respon-
dent recall though the use of photographs of common
pre-packaged therapies as well as individual anti-malarial
tablets. Results suggest that in many cases, people take a
cocktail with no identifiable anti-malarial. These results
do not necessarily mean that cocktails do not contain
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anti-malarials, rather that despite rigorous efforts, inter-
viewers and respondents could not identify any anti-
malarials in the cocktail. These results are contrary to
previous findings that cocktails acquired for malaria in
Cambodia more often than not reportedly contained an
anti-malarial [13]. There is need for more research to
understand the contents of cocktails acquired for
“malaria fever,” both in the context of a positive diagnos-
tic test results and in the case of no test. While it is possi-
ble that these cocktails contain full-course treatments, it
is also likely that they do not, which is a concern both for
the individual patient and for resistance containment
efforts.
Findings from this study show that the majority of provi-
ders in both public and private outlets are familiar with
the first-line treatment for malaria in Cambodia. The rea-
son that providers sell/distribute cocktails rather than full-
courses treatments, including pre-packaged ACT, particu-
larly given reasonable availability and price, is not well
understood. From a research perspective, respondent
inability to report contents of their cocktail is a limiting
factor in understanding treatments acquired and con-
sumed. From a programme perspective, these limitations
to respondent recall suggest that there is little communi-
cation between providers and clients on cocktail contents
and instructions for correct adherence. CNM survey
results suggest that there is little demand for full-course
treatment; only 39% of household respondents indicated
awareness of the need to adhere to the full treatment
course [7]. Raising awareness among the general popula-
tion at risk for malaria and encouraging acquisition of full-
course pre-packaged therapies are critical to improving
malaria treatment in Cambodia.
Conclusion
Evidence concerning the availability, price and volumes
of anti-malarials moving through the public and private
sectors suggests that the anti-malarial market in Cambo-
dia is favourable for both effective fever management and
prevention of the spread of artemisinin drug resistance.
Sale/distribution of artemisinin monotherapies is still a
problem but is relatively low, and sale/distribution of
ACT relative to other anti-malarial treatments is high.
However, the problem emerging from household survey
research is that many “malaria fevers” are not confirmed
through diagnostic testing - particularly when treatment
is sought in the private sector, and “malaria fever” is
most commonly treated with cocktail treatments - many
of which do not contain identifiable anti-malarial drugs.
There is evidence to suggest that positive diagnostic test
results are not consistently treated appropriately, particu-
larly in the private sector. More information is needed to
better understand factors that influence provider and cli-
ent respect for test results. There is urgent need to
address the private provider practice of prescribing drug
cocktails and consumer preferences for cocktail treat-
ment, particularly given the fact that treatment for
“malaria fever” is frequently sought from private provi-
ders. Evidence-based interventions that target provider
behaviour and aim to increase informed demand among
consumers for malaria diagnostic testing and full-course
national first-line anti-malarial treatments are needed.
These interventions will require additional information
to better understand the factors that contribute to cock-
tail treatment and that serve as barriers to diagnostic
testing and appropriate full-course treatments.
Acknowledgements
ACTwatch is funded by the Bill and Melinda Gates Foundation (#058992). We
thank the men and women who participated in this study. Many thanks are
also extended to the fieldworkers who collected these data under difficult
conditions during rainy seasons.
Author details
1Population Services International, Department of Malaria and Child Survival,
P.O. Box 14355-00800, Nairobi, Kenya. 2Population Services International
Cambodia, No. 29 Street 334, P.O. Box 153, BKK1 Chamcar Mon, Phnom
Penh, Kingdom of Cambodia. 3Department of Global Health and
Development, London School of Hygiene and Tropical Medicine, 15-17
Tavistock Place, London WC1H 9SH, UK. 4National Centre of Entomology,
Parasitological and Malaria control, House 372, St Monivong Vong, Boeung
Keng Kang I, Chamcar Mon, Phnom Penh, Kingdom of Cambodia.
Authors’ contributions
KOC designed the ACTwatch Cambodia household and outlet surveys and
data collection instruments. DC made contributions to the study design. ML
and HG are responsible for the particular analyses presented in this paper.
HG and SP made contributions to field work, data cleaning and analyses
presented in ACTwatch outlet and household study reports. TS, SY and AS
assisted with interpretation of findings. All authors read and approved the
final manuscript.
Competing interests
Henrietta Allen is the Malaria Programme Technical Advisor for PSI/
Cambodia.
Received: 29 July 2011 Accepted: 31 October 2011
Published: 31 October 2011
References
1. WHO: World malaria report 2010 Geneva: WHO; 2010.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, von
Seidlein L: Artemisinin resistance: current status and scenarios for
containment. Nature 2010, 8:272-280.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Arie F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ,
Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium
falciparum malaria. NEJM 2010, 361:455-467.
4. Montagu D: Large-scale malaria treatment in the private sector: a case study
of the Cambodian experience San Francisco: The Global Health Group, Global
Health Sciences, University of California, San Francisco; 2010.
5. Moszynski P: Cambodia closes illegal pharmacies to protect drugs. BMJ
2010, 340:c2622.
6. Yasuoka J, Poudel K, Poudel-Tandukar K, Nguon C, Ly P, Socheat D,
Jimba M: Assessing the quality of services of village malaria workers to
strengthen community-based malaria control in Cambodia. Malar J 2010,
9:109-120.
7. National Institute for Public Health, Malaria Consortium: Cambodia malaria
survey 2007 report National Institute of Public Health: Phnom Penh; 2008.
Littrell et al. Malaria Journal 2011, 10:328
http://www.malariajournal.com/content/10/1/328
Page 13 of 14
8. ACTwatch: Evidence for Malaria Medicines Policy. [http://www.actwatch.
info].
9. Shewchuk T, O’Connell K, Goodman C, Hanson K, Chapman S, Chavasse D:
The ACTwatch project: Methods to describe antimalarial markets in
seven countries. Malar J .
10. MEASURE DHS Demographic and Health Surveys. [http://www.
measuredhs.com].
11. Rutstein SO, Johnson K: The DHS wealth index. DHS Comparative Reports No.
6 Calverton, MD: ORC Macro; 2004.
12. Lon CT, Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, Sokhan C,
Blum N, Christophel EM, Smine A: Counterfeit and substandard
antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg 2006,
100:1019-1024.
13. Yeung S, Van Damme W, Socheat D, White NJ, Mills A: Access to
artemisinin combination therapy for malaria in remote areas of
Cambodia. Malar J 2008, 7:96-110.
14. WHO: Guidelines for the treatment of malaria, Second edition 2010 Geneva:
WHO; 2010.
15. The Global Fund: Round 9 Application: Cambodia Geneva: The Global Fund;
2009.
16. Chareonkul C, Khun VL, Boonshuyar C: Rational drug use in Cambodia:
Study of three pilot health centers in Kampong Thom province.
Southeast Asian J Trop Med Int Health 2002, 33:418-424.
17. Tawfik L: Mosquitoes, malaria and Malarine: A qualitative study on malaria
drug use in Cambodia. Submitted to the US Agency for International
Development by the Rational Pharmaceutical Management Plus Program
Arlington, VA: Management Sciences for Health; 2005.
18. Yeung S, White NJ: How do patients use antimalarial drugs? A review of
the evidence. Trop Med Int Health 2005, 10:121-138.
19. Yeung S, Patouillard E, Allen H, Socheat D: Socially-marketed rapid
diagnostic tests and ACT in the private sector: ten years of experience
in Cambodia. Malar J 10:243-258.
doi:10.1186/1475-2875-10-328
Cite this article as: Littrell et al.: Case management of malaria fever in
Cambodia: results from national anti-malarial outlet and household
surveys. Malaria Journal 2011 10:328.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Littrell et al. Malaria Journal 2011, 10:328
http://www.malariajournal.com/content/10/1/328
Page 14 of 14
